Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib and albumin-bound docetaxel in MET-altered advanced solid tumors
NCT06947291Phase 2Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glumetinib in gastric cancer (GC), gastroesophageal junction adenocarcinoma and solid tumor (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity up to 24 months, Adverse Events and Serious Adverse Events up to 24 months and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
glumetinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT06947291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947291.